Last reviewed · How we verify
velmanase
velmanase is a drug. It is currently in unknown development for Alpha-mannosidosis.
At a glance
| Generic name | velmanase |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Approved indications
- Alpha-mannosidosis
Common side effects
Key clinical trials
- A Real-world Analysis of Pharmacodynamic Response to Velmanase Alfa (Lamzede®) Treatment in Patients With Alpha-Mannosidosis Less Than 3 Years of Age (N/A)
- A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated Velmanase Alfa (Recombinant Human Alpha-mannosidase) Treatment in Pediatric Patients Below 6 Years o (Phase 2)
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis (Phase 3)
- NCT04959240 (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- velmanase CI brief — competitive landscape report
- velmanase updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about velmanase
What is velmanase?
velmanase is a pharmaceutical drug, indicated for Alpha-mannosidosis.
What is velmanase used for?
velmanase is indicated for Alpha-mannosidosis.
What development phase is velmanase in?
velmanase is in unknown.
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Alpha-mannosidosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing